Publication of the securities note having obtained visa no. 17-297 of the AMF in connection with the capital increase of GenSight Biologics

GenSight Biologics launches a capital increase of approximately €20 million

GenSight Biologics Appoints Mohamed Genead as Chief Medical Officer

GenSight Biologics Announces the Filing of its 2016 Registration Document

GenSight Biologics to Attend Upcoming Investor Conferences

GenSight Biologics Reports Full Year 2016 Financial Results

GenSight Biologics reports its cash position as of September 30, 2016

GenSight Biologics confirms the success of its IPO by exercising 88.9% of the over-allotment option

GenSight Biologics announces the implementation of a liquidity contract with Oddo & Cie

GenSight Biologics announces successful IPO on Euronext Paris